Guidance
Evidence-based recommendations on ClearGuard HD antimicrobial barrier caps for preventing haemodialysis catheter-related bloodstream infections.
Implementation
NICE has developed tools and resources, in association with relevant stakeholders, to help organisations put this guidance into practice.
Is this guidance up to date?
Next review: 2024
Guidance development process
How we develop NICE medical technologies guidance
NICE medical technologies guidance addresses specific technologies notified to NICE by companies. The ‘case for adoption’ is based on the claimed advantages of introducing the specific technology compared with current management of the condition. This case is reviewed against the evidence submitted and expert advice.
If the case for adopting the technology is supported, the specific recommendations are not intended to limit use of other relevant technologies that may offer similar advantages. If the technology is recommended for use in research, the recommendations are not intended to preclude the use of the technology but to identify further evidence which, after evaluation, could support a recommendation for wider adoption.
This guidance replaces NICE’s medtech innovation briefing on ClearGuard HD Antimicrobial Barrier Cap for preventing haemodialysis catheter-related bloodstream infections (MIB234).